8-K: Rallybio Reduces At-the-Market Offering Size with TD Cowen

Rallybio Corporation amended its sales agreement with TD Cowen, reducing the potential offering size of its common stock from $100 million to $9.55 million.

Summary

• Rallybio Corporation and TD Securities (USA) LLC (formerly Cowen and Company, LLC) amended their sales agreement on March 13, 2025.
• The amendment reduces the aggregate offering price of Rallybio's common stock that can be sold under the agreement from up to $100 million to up to $9.55 million.
• TD Cowen will use commercially reasonable efforts to sell the shares from time to time based on Rallybio's instructions.
• TD Cowen is entitled to a commission of up to 3.0% of the gross proceeds from the shares sold.
• Sales will be made at market prices through an at-the-market offering, potentially on the Nasdaq Global Select Market.
• Rallybio is not obligated to sell any shares and can suspend or terminate the agreement at any time.
• As of March 13, 2025, Rallybio has sold $0 of shares under the Sales Agreement.
• The company will not sell shares exceeding one-third of its public float in any twelve-month period if the public float remains below $75.0 million.
• The aggregate market value of the company's outstanding voting and non-voting common equity held by non-affiliates was approximately $28,655,118 as of March 13, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant reduction in the offering size, which could indicate financial constraints or a less optimistic outlook. However, the company retains flexibility and has not yet sold any shares under the agreement.

Positives

• Rallybio retains the flexibility to suspend or terminate the sales agreement at any time.
• The company has no obligation to sell any of the shares.

Negatives

• The reduced offering size may limit Rallybio's ability to raise capital through this agreement.
• The company's public float is below $75 million, which restricts the amount of shares it can sell in a twelve-month period.

Risks

• Market conditions may affect Rallybio's ability to sell shares at favorable prices.
• The company's low public float could further limit its ability to raise capital.
• There is no guarantee that TD Cowen will be able to sell any shares under the agreement.

Future Outlook

Rallybio may issue and sell shares of its common stock through TD Cowen from time to time, subject to the terms and conditions of the amended sales agreement.

Industry Context

At-the-market offerings are a common way for biotech companies to raise capital. The reduction in offering size may reflect a change in the company's capital needs or market conditions.

Comparison to Industry Standards

• Comparable companies such as BioNTech and Moderna have also utilized at-the-market offerings to raise capital.
• The commission rate of 3.0% is within the typical range for at-the-market offerings.
• The size of the offering is relatively small compared to some other biotech companies, which may indicate a more conservative approach to capital raising.

Stakeholder Impact

• Shareholders may be affected by the potential dilution from the issuance of new shares.
• The reduced offering size may impact the company's ability to fund its research and development programs.

Next Steps

• Rallybio may choose to issue and sell shares of its common stock through TD Cowen.
• TD Cowen will attempt to sell the shares based on Rallybio's instructions.
• The company will monitor its public float to ensure compliance with the sales agreement.

Key Dates